Pramlintide
Treatment for Diabetes Mellitus Type 1
Typical Dosage: 60-120 mcg subcutaneously before each major meal
Effectiveness
65%
Safety Score
60%
Clinical Trials
38
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
60-120 mcg subcutaneously before each major meal
Time to Effect
Immediate (postprandial glucose), months for weight effects
Treatment Duration
Lifetime (as needed)
Evidence Quality
MODERATEConfidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$7,000
Monitoring:$100
Side Effect Mgmt:$300
Total Annual:$7,400
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$200,000/QALY
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$12,333
Pramlintide Outcomes
for Diabetes Mellitus Type 1
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+60%
Common Side Effects
Nausea
+30%
Anorexia
+15%
Severe Hypoglycemia (with insulin)
+8%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
19 completed trials for Pramlintide in Diabetes Mellitus Type 1
A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
NCT00313183COMPLETEDPHASE2
12 participants
INTERVENTIONAL
Aurora, United States +2 more
Started: Apr 1, 2006
Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus
NCT00108004COMPLETEDPHASE3
400 participants
INTERVENTIONAL
Anaheim, United States +47 more
Started: Apr 1, 2003
Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus
NCT00107107COMPLETEDPHASE3
190 participants
INTERVENTIONAL
Tempe, United States +24 more
Started: Nov 1, 2002
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
NCT00229658COMPLETED
1.3K participants
OBSERVATIONAL
Birmingham, United States +106 more
Started: Sep 1, 2005
Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus
NCT00442767COMPLETEDPHASE4
8 participants
INTERVENTIONAL
The Bronx, United States
Started: Feb 1, 2007
Evaluation of the Bioavailability of Pramlintide
NCT00042471COMPLETEDPHASE2
75 participants
INTERVENTIONAL
Orlando, United States +3 more
Started: Jun 1, 2002
Pramlintide in Adolescents With Type 1 Diabetes
NCT00842075COMPLETEDNA
10 participants
INTERVENTIONAL
Aurora, United States
Started: Dec 1, 2006
Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control
NCT00042458COMPLETEDPHASE3
296 participants
INTERVENTIONAL
Mesa, United States +32 more
Started: Apr 1, 2002
Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide
NCT00489645COMPLETEDNA
27 participants
INTERVENTIONAL
Started: Jan 1, 2005
Continuous Subcutaneous Infusion of Pramlintide and Insulin
NCT00291772COMPLETEDPHASE4
13 participants
INTERVENTIONAL
Houston, United States
Started: Jan 1, 2006
A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus
NCT03916640COMPLETEDPHASE1
24 participants
INTERVENTIONAL
Neuss, Germany
Started: Jan 4, 2019
Evaluation of the Effect of Pramlintide on Satiety and Food Intake
NCT00042601COMPLETEDPHASE2
51 participants
INTERVENTIONAL
Adelaide, Australia
Started: Jul 1, 2002
Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus
NCT01839370COMPLETEDNA
9 participants
INTERVENTIONAL
Charlottesville, United States
Started: Jul 1, 2013
The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes
NCT00206297COMPLETEDPHASE3
20 participants
INTERVENTIONAL
Houston, United States
Started: Oct 1, 2003
Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus
NCT02500979COMPLETEDPHASE1
34 participants
INTERVENTIONAL
Chula Vista, United States +2 more
Started: Aug 17, 2015
Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM
NCT01708044COMPLETEDPHASE1
32 participants
INTERVENTIONAL
Portland, United States
Started: Nov 1, 2012
A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus
NCT03512236COMPLETEDPHASE1
24 participants
INTERVENTIONAL
Neuss, Germany
Started: Apr 25, 2018
Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia
NCT01269047COMPLETEDPHASE4
37 participants
INTERVENTIONAL
The Bronx, United States
Started: Aug 1, 2009
Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas
NCT04163874COMPLETEDNA
36 participants
INTERVENTIONAL
Montreal, Canada
Started: Feb 14, 2020
Showing 20 of 38 total trials